[go: up one dir, main page]

PE20000432A1 - Compuestos triciclicos sustituidos - Google Patents

Compuestos triciclicos sustituidos

Info

Publication number
PE20000432A1
PE20000432A1 PE1999000314A PE00031499A PE20000432A1 PE 20000432 A1 PE20000432 A1 PE 20000432A1 PE 1999000314 A PE1999000314 A PE 1999000314A PE 00031499 A PE00031499 A PE 00031499A PE 20000432 A1 PE20000432 A1 PE 20000432A1
Authority
PE
Peru
Prior art keywords
carbamoylcarbazol
methyl
acid
oxyacetic
oxyacetic acid
Prior art date
Application number
PE1999000314A
Other languages
English (en)
Inventor
Alan Hite Gary
David Mihelich Edward
Anne Bastian Jolie
James Bach Nicholas
Jon Sall Daniel
Theodore Vasileff Robert
Dean Kinnick Michael
Michael Morin Junior John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20000432A1 publication Critical patent/PE20000432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS TRICICLICOS DERIVADOS DE CARBAZOL TALES COMO: ACIDO {9-[(FENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO; ACIDO [9-BENCIL-5-CARBAMOIL-1-FLUOROCARBAZOL-4-IL]OXIACETICO; ACIDO {9-[(3-FLUOROFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO; ACIDO {9-[(3-CLOROFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO; SAL SODICA DEL ACIDO {9-[(3-TRIFLUOROMETILFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO; SAL SODICA DEL ACIDO {9-[(2-METILFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO, SAL SODICA DEL ACIDO {9-[(3-METILFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO, SAL SODICA DEL ACIDO {9-[(3-TRIFLUOROMETOXIFENIL)METIL]-5-CARBAMOILCARBAZOL-4-IL}OXIACETICO, ACIDO [9-BENCIL-5-CARBAMOIL-1-CLOROCARBAZOL-4-IL]OXIACETICO, ACIDO [9-[(CICLOHEXIL)METIL]-5-CARBAMOILCARBAZOL-4-IL]OXIACETICO, ACIDO [9-[(CICLOPENTIL)METIL]-5-CARBAMOILCARBAZOL-4-IL]OXIACETICO; LOS QUE INHIBEN LA LIBERACION DE ACIDOS GRASOS INDUCIDA POR FOSFOLIPASA A2 SECRETORA NO PANCREATICA HUMANA (sPLA2) INHIBIENDO ASI LA CASCADA DE ACIDO ARAQUIDONICO POR LO QUE PUEDEN SER UTILES PARA EL TRATAMIENTO DE SEPTICEMIA, CHOQUE SEPTICO, ARTRITIS REUMATOIDE, OSTEOARTRITIS, APOPLEJIA, APOPTOSIS, ASMA, BRONQUITIS CRONICA, BRONQUITIS AGUDA, FIBROSIS QUISTICA, ENFERMEDAD INFLAMATORIA DEL INTESTINO
PE1999000314A 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos PE20000432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
PE20000432A1 true PE20000432A1 (es) 2000-05-23

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
PE1999000314A PE20000432A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos
PE1999000320A PE20000476A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE1999000320A PE20000476A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos

Country Status (30)

Country Link
EP (2) EP0950657B1 (es)
JP (2) JP4435330B2 (es)
KR (2) KR100586761B1 (es)
CN (1) CN1149193C (es)
AR (2) AR018186A1 (es)
AT (2) ATE268756T1 (es)
AU (2) AU753436B2 (es)
BR (2) BR9901279A (es)
CA (2) CA2269262A1 (es)
CO (2) CO5031247A1 (es)
CZ (2) CZ136999A3 (es)
DE (2) DE69918590T2 (es)
DK (1) DK0950657T3 (es)
DZ (1) DZ2769A1 (es)
EA (2) EA002816B1 (es)
ES (2) ES2226286T3 (es)
HU (2) HUP9901221A3 (es)
ID (2) ID23761A (es)
IL (2) IL129485A0 (es)
NO (2) NO312240B1 (es)
NZ (3) NZ335253A (es)
PE (2) PE20000432A1 (es)
PL (2) PL332566A1 (es)
PT (1) PT950657E (es)
SG (2) SG81976A1 (es)
SI (1) SI0950657T1 (es)
TR (2) TR199900843A2 (es)
TW (1) TWI238160B (es)
YU (2) YU18999A (es)
ZA (2) ZA992771B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
EP1214041A2 (en) * 1998-12-21 2002-06-19 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビター
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267824A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
CA2431028A1 (en) 2000-12-18 2002-06-27 Ho-Shen Lin Tetracyclic carbazole derivates and their use as spla2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
AU2009230127B2 (en) 2008-03-26 2011-12-22 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
PE20091838A1 (es) 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
EP2379538A4 (en) * 2009-01-22 2013-01-02 Orchid Res Lab Ltd HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
RU2569061C2 (ru) 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CA2889642A1 (en) * 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
WO2014083113A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Crystallization process of tricyclic indole derivatives
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
HUP9901984A3 (en) * 1995-12-13 2001-01-29 Lilly Co Eli Naphthyl acetamides as spla2 inhibitors, use thereof and pharmaceutical compositions containing these compounds
BR9713261A (pt) * 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
TR199900843A2 (xx) 2000-02-21
KR19990083233A (ko) 1999-11-25
CN1149193C (zh) 2004-05-12
HUP9901220A3 (en) 2001-11-28
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
CO5011054A1 (es) 2001-02-28
EP0950657A3 (en) 2001-08-16
NO991821D0 (no) 1999-04-16
CA2269262A1 (en) 1999-10-17
HU9901221A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
IL129483A0 (en) 2000-02-29
NO991821L (no) 1999-10-18
EA199900303A2 (ru) 1999-10-28
TR199900853A3 (tr) 1999-11-22
CO5031247A1 (es) 2001-04-27
IL129485A0 (en) 2000-02-29
ZA992771B (en) 2002-04-18
AU2381799A (en) 1999-10-28
EP0952149A2 (en) 1999-10-27
NO314400B1 (no) 2003-03-17
PL332565A1 (en) 1999-10-25
DE69917833D1 (de) 2004-07-15
DE69918590D1 (de) 2004-08-19
PL332566A1 (en) 1999-10-25
ATE271037T1 (de) 2004-07-15
EA199900301A2 (ru) 1999-10-28
HUP9901221A3 (en) 2001-11-28
AR018593A1 (es) 2001-11-28
HU9901220D0 (en) 1999-06-28
NO991822L (no) 1999-10-18
KR19990083232A (ko) 1999-11-25
ES2222663T3 (es) 2005-02-01
AU753436B2 (en) 2002-10-17
HU9901221D0 (en) 1999-06-28
ES2226286T3 (es) 2005-03-16
EA199900303A3 (ru) 2000-04-24
ATE268756T1 (de) 2004-06-15
EP0950657B1 (en) 2004-07-14
CA2269246C (en) 2009-08-25
SG81977A1 (en) 2001-07-24
YU18999A (sh) 2002-08-12
EA199900301A3 (ru) 2000-04-24
AU2381999A (en) 1999-10-28
SG81976A1 (en) 2001-07-24
DZ2769A1 (fr) 2003-12-01
AU753547B2 (en) 2002-10-24
PE20000476A1 (es) 2000-06-02
BR9902365A (pt) 2001-04-24
BR9901279A (pt) 2000-05-02
TR199900853A2 (xx) 1999-11-22
TWI238160B (en) 2005-08-21
PT950657E (pt) 2004-11-30
KR100586761B1 (ko) 2006-06-08
AR018186A1 (es) 2001-10-31
NO312240B1 (no) 2002-04-15
ID23287A (id) 2000-04-05
JP2000026416A (ja) 2000-01-25
NO991822D0 (no) 1999-04-16
EP0950657A2 (en) 1999-10-20
EP0952149B1 (en) 2004-06-09
DE69918590T2 (de) 2005-07-21
JP4435330B2 (ja) 2010-03-17
HU9901220A (hu) 2000-04-28
CA2269246A1 (en) 1999-10-17
CZ136999A3 (cs) 1999-11-17
DE69917833T2 (de) 2005-07-14
DK0950657T3 (da) 2004-11-22
EP0952149A3 (en) 2001-08-16
ZA992772B (en) 2002-07-16
CZ137099A3 (cs) 1999-11-17
JPH11322713A (ja) 1999-11-24
NZ335251A (en) 2000-11-24
EA002347B1 (ru) 2002-04-25
SI0950657T1 (en) 2005-02-28
ID23761A (id) 2000-05-11
YU19199A (sh) 2002-08-12
NZ507564A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
PE20000432A1 (es) Compuestos triciclicos sustituidos
YU19299A (sh) Supstituisani tricikli
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
BRPI0512690A (pt) análogos de fosfonato de compostos inibidores de hiv
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
AR067440A1 (es) ÁCIDO BILIAR SINTETICO, UNA COMPOSICION QUE LO COMPRENDE, UN METODO PARA SU PREPARACION, COMPUESTOS INTERMEDIARIOS DE SíNTESIS Y SU EMPLEO EN LA ELIMINACION DE LOS DEPoSITOS DE GRASA CORPORAL
AR067355A1 (es) Procesos para la preparacion de pirazoles
AR013384A1 (es) Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4
BR112012008939A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt2
WO2009065530A3 (de) Verfahren zur herstellung von acylglycinaten
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
CR11362A (es) Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol
BR112012022455A2 (pt) composição de poliolefina, batelada mestre, cabo, uso de uma composição de poliolefina, uso de uma batelada mestre e uso de um derivado de benzila
BR0016179A (pt) Método para preparar lisofosfatidiletanolamina
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
BR9915223A (pt) Processo para a preparação contìnua de ésteres alquìlicos de ácido (met) acrìlico
MA32290B1 (fr) Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives
EA199900304A2 (ru) Замещенные трициклические соединения
Bakef et al. Synthesis of D-and L-myo-inositol 1-phosphorothioate, substrates for inositol monophosphatase
ES2195182T3 (es) Fenil glioxamidas como inhibidores de spla2.
Go et al. Concise, diastereoconvergent synthesis of endiandric-type tetracycles by iterative cross coupling
AR071699A1 (es) Uso de lisofosfolipidos para tratar la inflamacion. composicion.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed